Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Dividends Paid - Common (2016 - 2025)

Historic Dividends Paid - Common for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $988000.0.

  • Utah Medical Products' Dividends Paid - Common fell 608.37% to $988000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 580.01%. This contributed to the annual value of $4.3 million for FY2024, which is 51.38% down from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' Dividends Paid - Common is $988000.0, which was down 608.37% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Utah Medical Products' Dividends Paid - Common peaked at $8.3 million during Q4 2021, and registered a low of $988000.0 during Q3 2025.
  • In the last 5 years, Utah Medical Products' Dividends Paid - Common had a median value of $1.1 million in 2022 and averaged $1.5 million.
  • As far as peak fluctuations go, Utah Medical Products' Dividends Paid - Common skyrocketed by 71933.27% in 2021, and later tumbled by 8741.17% in 2022.
  • Utah Medical Products' Dividends Paid - Common (Quarter) stood at $8.3 million in 2021, then crashed by 87.41% to $1.1 million in 2022, then rose by 1.9% to $1.1 million in 2023, then dropped by 3.08% to $1.0 million in 2024, then dropped by 4.82% to $988000.0 in 2025.
  • Its Dividends Paid - Common stands at $988000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $1.0 million for Q1 2025.